AUROBINDO

PRESS RELEASE

17th May 2011

Aurobindo Pharma receives approvals for Risperidone tablets, oral solution and Alendronate tablets from TGA, Australia

Aurobindo Pharma Limited is pleased to announce that its wholly owned subsidiary Aurobindo Pharma Australia Pty Ltd has received approvals from Therapeutic Goods Administration (TGA), Government of Australia for the registration of Risperidone Tablets 0.5mg, 1mg, 2mg, 3mg, 4mg and Oral Solution 1mg/1ml and Alendronate Tablets 70mg.

Risperidone Tablets and Oral Solution are indicated in the treatment schizophrenia and falls under the neurological (CNS) segment. Alendronate Tablets 70mg are indicated for the treatment and prevention of osteoporosis.

Risperdione products has a market size of approximately US$ 27.5 Million and Alendronate has US$14 million for the twelve months ending September 2010 according to IMS.

Aurobindo now has 8 approvals from TGA, Australia.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:
Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com